This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Vernal Keratoconjunctivitis Market

Market Insights on Vernal Keratoconjunctivitis covering sales outlook, demand forecast & up-to-date key trends

Vernal Keratoconjunctivitis Market By Treatment, Dosage Type, Drug Form, Distribution Channel & Region – Forecast 2023–2033

Vernal Keratoconjunctivitis Market Snapshot (2023-2033)

The global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR of 6% in the forecast period 2023-2033. One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations. The market for Vernal Keratoconjunctivitis registered a CAGR of 4% in the historical period 2017-2022.

Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.

Report Attribute

Details

Expected Market Value (2023)

US$ 436.9 Million

Anticipated Forecast Value (2033)

US$ 782.42 Million

Projected Growth Rate (2023-2033)

6% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2017-2022 Vernal Keratoconjunctivitis Market Demand Analysis vs. Forecast 2023-2033

According to market research and competitive intelligence provider Future Market Insights- the market for Vernal Keratoconjunctivitis reflected a value of 4% during the historical period, 2017-2022. According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, increasing prevalence of conjunctivitis during the pandemic had the potential to drive the demand for the market.

However, the relaxation of strict lockdowns started to contribute to the increase in the patient inflow for vernal keratoconjunctivitis treatment, adding to the growth of the market. Thus, the market for Vernal Keratoconjunctivitis is expected to register a CAGR of 6% in the forecast period 2023-2033.

Which are Some Prominent Drivers of the Vernal Keratoconjunctivitis Market?

Increasing incidence of Vernal Keratoconjunctivitis disease to push the market growth

The increasing prevalence of Vernal Keratoconjunctivitis disease is one of the biggest drivers of the market. As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years.

Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe.

With the increasing prevalence and awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens. Treatment for vernal keratoconjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Vernal Keratoconjunctivitis Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Vernal Keratoconjunctivitis, less awareness of Vernal Keratoconjunctivitis disease, and insubstantial treatment options are hampering the market growth. The global conjunctivitis market is anticipated to be constrained by factors such as low illness awareness and inadequate pharmaceutical coverage in developing nations.

Region-Wise Insights

How is the Market for Vernal Keratoconjunctivitis Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling growth of Vernal Keratoconjunctivitis in Asia Pacific

The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region. Conjunctivitis is quite prevalent in nations like India. For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies. The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.

In addition to these factors, an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment. Over the anticipated time, these factors will boost market expansion in the region.

What are the Factors Boosting the Market for Vernal Keratoconjunctivitis in North America?

High prevalence of ophthalmic allergies shaping landscape for Vernal Keratoconjunctivitis in North America

North America is anticipated to acquire a market share of about 20% in the forecast period. This growth is attributable to the increasing awareness of ophthalmic allergies. This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth. A country like the United States has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.

As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Such prevalence of conjunctivitis in the United States is pushing the demand for an effective treatment, thereby contributing to the market's growth during the forecast period.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

Based on Dosage Form, Which Segment is Pushing the Market Growth?

Superior efficiency of tablet consumption bolstering the growth

On the basis of treatment, the segment has been divided into gel, ointment, tablets and others. The tablets are widely used by patients suffering from vernal keratoconjunctivitis which is further triggering the market growth. Owing to an increased usage of these tablets in the treatment, as they help in the faster recovery of the disease, players are focussing on launching new and sophisticated products.

Start-Up in the Vernal Keratoconjunctivitis Market

Key start-up players in the Vernal Keratoconjunctivitis market are-

  • In March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company aims to create an inventive ophthalmic therapy to enhance vision for individuals across the globe. The company announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF, which is a topical preservative-free ophthalmic solution for treating presbyopia.
  • In October 2021, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop innovative genomic medicines using CRISPR/Cas9 technology for treating ocular diseases.

Market Competition

Key players in the Vernal Keratoconjunctivitis market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.

  • In May 2022 Santen Pharmaceutical received approval for Verkazia from the National Medical Products Administration (NMPA) in China through its legal entity for treating severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and above.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 436.9 Million

Market Value in 2033

US$ 782.42 Million

Growth Rate

CAGR of 6% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2017-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in USD Million and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Treatment
  • Drug type
  • Dosage Form
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

Allakos, iCo Therapeutics, Akari Therapeutics, and Santen

Customization

Available Upon Request

Key Segments Profiled in the Vernal Keratoconjunctivitis Industry Survey

Treatment:

  • Mast Cell Stabilizers
  • Antihistamines
  • Nonsteroidal Anti-inflammatory Drugs - NSAIDs
  • Topical Corticosteroids
  • Cyclosporine
  • Tacrolimus
  • Others

Drug Type:

  • Bertilimumab
  • Verkazia
  • Lodoxamide
  • Tacrolimus
  • Antolimab
  • Nomacopan
  • Others

Dosage form:

  • Ointment
  • Gel
  • Tablets
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA

Frequently Asked Questions

From 2017-2022, the Vernal Keratoconjunctivitis market grew at CAGR of 4%.

The global Vernal Keratoconjunctivitis market is expected to grow with a 6% CAGR during 2023-2033.

As of 2033, the Vernal Keratoconjunctivitis market is expected to reach US$ 782.42 Million

According to the FMI analysis, Hospital pharmacies account for the largest market share.

Tablets are expected to show the highest CAGR owing to the increasing demand for new approaches.

North America is expected to possess 20% market share for the Vernal Keratoconjunctivitis market.

The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033

        5.3.1. Bertilimumab

        5.3.2. Verkazia

        5.3.3. Lodoxamide

        5.3.4. Tacrolimus

        5.3.5. Antolimab

        5.3.6. Nomacopan

        5.3.7. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033

        6.3.1. Mast Cell Stabilizers

        6.3.2. Antihistamines

        6.3.3. Nonsteroidal Anti-inflammatory Drugs - NSAIDs

        6.3.4. Topical Corticosteroids

        6.3.5. Cyclosporine

        6.3.6. Tacrolimus

        6.3.7. Others

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Dosage Form

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Dosage Form , 2018-2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Dosage Form , 2023-2033

        7.3.1. Gel

        7.3.2. Ointment

        7.3.3. Tablet

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By Dosage Form , 2018-2022

    7.5. Absolute $ Opportunity Analysis By Dosage Form , 2023-2033

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018-2022

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        8.3.1. Hospital Pharmacy

        8.3.2. Retail Pharmacy

        8.3.3. Online Pharmacy

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018-2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023-2033

9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific

        9.3.5. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. U.S.

            10.2.1.2. Canada

        10.2.2. By Drug Type

        10.2.3. By Treatment

        10.2.4. By Dosage Form

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Treatment

        10.3.4. By Dosage Form

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Type

        11.2.3. By Treatment

        11.2.4. By Dosage Form

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Treatment

        11.3.4. By Dosage Form

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Type

        12.2.3. By Treatment

        12.2.4. By Dosage Form

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Treatment

        12.3.4. By Dosage Form

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

            13.2.1.4. Singapore

            13.2.1.5. Thailand

            13.2.1.6. Indonesia

            13.2.1.7. Australia

            13.2.1.8. New Zealand

            13.2.1.9. Rest of Asia Pacific

        13.2.2. By Drug Type

        13.2.3. By Treatment

        13.2.4. By Dosage Form

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Treatment

        13.3.4. By Dosage Form

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Type

        14.2.3. By Treatment

        14.2.4. By Dosage Form

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Treatment

        14.3.4. By Dosage Form

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Type

            15.1.2.2. By Treatment

            15.1.2.3. By Dosage Form

            15.1.2.4. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Type

            15.2.2.2. By Treatment

            15.2.2.3. By Dosage Form

            15.2.2.4. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Type

            15.3.2.2. By Treatment

            15.3.2.3. By Dosage Form

            15.3.2.4. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Type

            15.4.2.2. By Treatment

            15.4.2.3. By Dosage Form

            15.4.2.4. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Type

            15.5.2.2. By Treatment

            15.5.2.3. By Dosage Form

            15.5.2.4. By Distribution Channel

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Type

            15.6.2.2. By Treatment

            15.6.2.3. By Dosage Form

            15.6.2.4. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Type

            15.7.2.2. By Treatment

            15.7.2.3. By Dosage Form

            15.7.2.4. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Type

            15.8.2.2. By Treatment

            15.8.2.3. By Dosage Form

            15.8.2.4. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Type

            15.9.2.2. By Treatment

            15.9.2.3. By Dosage Form

            15.9.2.4. By Distribution Channel

    15.10. China

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Type

            15.10.2.2. By Treatment

            15.10.2.3. By Dosage Form

            15.10.2.4. By Distribution Channel

    15.11. Japan

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Type

            15.11.2.2. By Treatment

            15.11.2.3. By Dosage Form

            15.11.2.4. By Distribution Channel

    15.12. South Korea

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Type

            15.12.2.2. By Treatment

            15.12.2.3. By Dosage Form

            15.12.2.4. By Distribution Channel

    15.13. Singapore

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Type

            15.13.2.2. By Treatment

            15.13.2.3. By Dosage Form

            15.13.2.4. By Distribution Channel

    15.14. Thailand

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Type

            15.14.2.2. By Treatment

            15.14.2.3. By Dosage Form

            15.14.2.4. By Distribution Channel

    15.15. Indonesia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Type

            15.15.2.2. By Treatment

            15.15.2.3. By Dosage Form

            15.15.2.4. By Distribution Channel

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Type

            15.16.2.2. By Treatment

            15.16.2.3. By Dosage Form

            15.16.2.4. By Distribution Channel

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Type

            15.17.2.2. By Treatment

            15.17.2.3. By Dosage Form

            15.17.2.4. By Distribution Channel

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Type

            15.18.2.2. By Treatment

            15.18.2.3. By Dosage Form

            15.18.2.4. By Distribution Channel

    15.19. South Africa

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Type

            15.19.2.2. By Treatment

            15.19.2.3. By Dosage Form

            15.19.2.4. By Distribution Channel

    15.20. Israel

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Type

            15.20.2.2. By Treatment

            15.20.2.3. By Dosage Form

            15.20.2.4. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Type

        16.3.3. By Treatment

        16.3.4. By Dosage Form

        16.3.5. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Santen

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Novartis Pharmaceuticals

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Senju Pharmaceutical

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Allakos

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. iCo Therapeutics

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Akari Therapeutics

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Alcon Vision LLC

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 3: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 4: Global Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 5: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Table 6: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 7: North America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 8: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 9: North America Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 10: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 12: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 13: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 14: Latin America Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 15: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 17: Europe Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 18: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 19: Europe Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 20: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Table 21: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 22: Asia Pacific Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 23: Asia Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 24: Asia Pacific Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 25: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Table 26: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 27: MEA Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 28: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 29: MEA Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033

Table 30: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Treatment, 2023-2033

Figure 3: Global Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 4: Global Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 5: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 9: Global Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 12: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 15: Global Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 18: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 21: Global Market Attractiveness by Drug Type, 2023-2033

Figure 22: Global Market Attractiveness by Treatment, 2023-2033

Figure 23: Global Market Attractiveness by Dosage Form , 2023-2033

Figure 24: Global Market Attractiveness by Distribution Channel, 2023-2033

Figure 25: Global Market Attractiveness by Region, 2023-2033

Figure 26: North America Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 27: North America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 28: North America Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 29: North America Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 30: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 34: North America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 37: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 40: North America Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 43: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 46: North America Market Attractiveness by Drug Type, 2023-2033

Figure 47: North America Market Attractiveness by Treatment, 2023-2033

Figure 48: North America Market Attractiveness by Dosage Form , 2023-2033

Figure 49: North America Market Attractiveness by Distribution Channel, 2023-2033

Figure 50: North America Market Attractiveness by Country, 2023-2033

Figure 51: Latin America Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 52: Latin America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 53: Latin America Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 54: Latin America Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 55: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 59: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 62: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 65: Latin America Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 68: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 71: Latin America Market Attractiveness by Drug Type, 2023-2033

Figure 72: Latin America Market Attractiveness by Treatment, 2023-2033

Figure 73: Latin America Market Attractiveness by Dosage Form , 2023-2033

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023-2033

Figure 75: Latin America Market Attractiveness by Country, 2023-2033

Figure 76: Europe Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 77: Europe Market Value (US$ Mn) by Treatment, 2023-2033

Figure 78: Europe Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 79: Europe Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 80: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 84: Europe Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 87: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 88: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 90: Europe Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 91: Europe Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 92: Europe Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 93: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 96: Europe Market Attractiveness by Drug Type, 2023-2033

Figure 97: Europe Market Attractiveness by Treatment, 2023-2033

Figure 98: Europe Market Attractiveness by Dosage Form , 2023-2033

Figure 99: Europe Market Attractiveness by Distribution Channel, 2023-2033

Figure 100: Europe Market Attractiveness by Country, 2023-2033

Figure 101: Asia Pacific Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 102: Asia Pacific Market Value (US$ Mn) by Treatment, 2023-2033

Figure 103: Asia Pacific Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 104: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 105: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 106: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 109: Asia Pacific Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 112: Asia Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 115: Asia Pacific Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 118: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 121: Asia Pacific Market Attractiveness by Drug Type, 2023-2033

Figure 122: Asia Pacific Market Attractiveness by Treatment, 2023-2033

Figure 123: Asia Pacific Market Attractiveness by Dosage Form , 2023-2033

Figure 124: Asia Pacific Market Attractiveness by Distribution Channel, 2023-2033

Figure 125: Asia Pacific Market Attractiveness by Country, 2023-2033

Figure 126: MEA Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 127: MEA Market Value (US$ Mn) by Treatment, 2023-2033

Figure 128: MEA Market Value (US$ Mn) by Dosage Form , 2023-2033

Figure 129: MEA Market Value (US$ Mn) by Distribution Channel, 2023-2033

Figure 130: MEA Market Value (US$ Mn) by Country, 2023-2033

Figure 131: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 132: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 134: MEA Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 135: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 136: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 137: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 138: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 139: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 140: MEA Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033

Figure 141: MEA Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033

Figure 142: MEA Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033

Figure 143: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033

Figure 144: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 145: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 146: MEA Market Attractiveness by Drug Type, 2023-2033

Figure 147: MEA Market Attractiveness by Treatment, 2023-2033

Figure 148: MEA Market Attractiveness by Dosage Form , 2023-2033

Figure 149: MEA Market Attractiveness by Distribution Channel, 2023-2033

Figure 150: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Ophthalmic Eye Drops Market

Published : May 2021

Healthcare

Conjunctivitis Market

Published : January 1970

Healthcare

Eye Infections Treatment Market

Published : February 2022

Healthcare

Ophthalmic Diagnostic Equipment Market

Published : February 2022

Google translate

Vernal Keratoconjunctivitis Market